Insider Transactions in Q1 2025 at Vertex Pharmaceuticals Inc (VRTX)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2025
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
244
-0.36%
|
$111,020
$455.06 P/Share
|
|
Feb 18
2025
|
Jonathan Biller EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,657
-8.6%
|
$753,935
$455.06 P/Share
|
|
Feb 18
2025
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
671
-5.85%
|
$305,305
$455.06 P/Share
|
|
Feb 14
2025
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,139
-2.79%
|
$990,357
$463.46 P/Share
|
|
Feb 14
2025
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,293
-3.26%
|
$1,061,659
$463.46 P/Share
|
|
Feb 14
2025
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,293
-3.5%
|
$1,061,659
$463.46 P/Share
|
|
Feb 14
2025
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,912
-4.46%
|
$885,256
$463.46 P/Share
|
|
Feb 14
2025
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
6,553
-4.82%
|
$3,034,039
$463.46 P/Share
|
|
Feb 14
2025
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
6,066
-20.16%
|
$2,808,558
$463.46 P/Share
|
|
Feb 14
2025
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,724
-3.52%
|
$1,261,212
$463.46 P/Share
|
|
Feb 14
2025
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,529
-5.19%
|
$707,927
$463.46 P/Share
|
|
Feb 14
2025
|
Jonathan Biller EVP and Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,504
-7.24%
|
$696,352
$463.46 P/Share
|
|
Feb 14
2025
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,293
-4.74%
|
$1,061,659
$463.46 P/Share
|
|
Feb 14
2025
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
564
-4.69%
|
$261,132
$463.46 P/Share
|
|
Feb 13
2025
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
2,525
-7.74%
|
$1,136,250
$450.83 P/Share
|
|
Feb 12
2025
|
Charles F Wagner Jr EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,655
+9.22%
|
-
|
|
Feb 12
2025
|
Jeffrey M Leiden Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
7,209
+18.1%
|
-
|
|
Feb 12
2025
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
BUY
Grant, award, or other acquisition
|
Direct |
6,211
+8.13%
|
-
|
|
Feb 12
2025
|
Jonathan Biller EVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,437
+17.6%
|
-
|
|
Feb 12
2025
|
Carmen Bozic EVP and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
5,546
+11.46%
|
-
|
|
Feb 12
2025
|
Reshma Kewalramani CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
19,015
+12.27%
|
-
|
|
Feb 12
2025
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
BUY
Grant, award, or other acquisition
|
Direct |
6,211
+7.48%
|
-
|
|
Feb 12
2025
|
Kristen Ambrose SVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,080
+14.74%
|
-
|
|
Feb 12
2025
|
Stuart A Arbuckle EVP, COO |
BUY
Grant, award, or other acquisition
|
Direct |
7,903
+9.26%
|
-
|
|
Feb 12
2025
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
BUY
Grant, award, or other acquisition
|
Direct |
6,211
+17.42%
|
-
|
|
Feb 12
2025
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,324
+9.91%
|
-
|
|
Feb 11
2025
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
310
-0.48%
|
$142,290
$459.83 P/Share
|
|
Feb 11
2025
|
Jonathan Biller EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,433
-17.37%
|
$1,575,747
$459.87 P/Share
|
|
Feb 11
2025
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Open market or private sale
|
Direct |
1,747
-7.0%
|
$801,873
$459.83 P/Share
|
|
Feb 11
2025
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,376
-12.15%
|
$631,584
$459.83 P/Share
|
|
Feb 10
2025
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,143
-3.22%
|
$1,000,781
$467.98 P/Share
|
|
Feb 10
2025
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,649
-4.31%
|
$1,237,083
$467.98 P/Share
|
|
Feb 10
2025
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
8,300
-6.63%
|
$3,876,100
$467.98 P/Share
|
|
Feb 10
2025
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,056
-2.83%
|
$960,152
$467.98 P/Share
|
|
Feb 10
2025
|
Jonathan Biller EVP and Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,632
-7.63%
|
$762,144
$467.98 P/Share
|
|
Feb 10
2025
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,142
-5.43%
|
$1,000,314
$467.98 P/Share
|
|
Feb 10
2025
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,220
-4.43%
|
$1,503,740
$467.98 P/Share
|
|
Feb 10
2025
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
876
-3.39%
|
$409,092
$467.98 P/Share
|
|
Feb 10
2025
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,142
-4.73%
|
$1,000,314
$467.98 P/Share
|
|
Feb 10
2025
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
591
-4.96%
|
$275,997
$467.98 P/Share
|
|
Feb 04
2025
|
Charles F Wagner Jr EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,376
+13.12%
|
-
|
|
Feb 04
2025
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
BUY
Grant, award, or other acquisition
|
Direct |
15,324
+10.03%
|
-
|
|
Feb 04
2025
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
BUY
Grant, award, or other acquisition
|
Direct |
17,376
+12.2%
|
-
|
|
Feb 04
2025
|
Carmen Bozic EVP and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
16,190
+18.25%
|
-
|
|
Feb 04
2025
|
Reshma Kewalramani CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
49,446
+17.85%
|
-
|
|
Feb 04
2025
|
Jeffrey M Leiden Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
15,414
+37.76%
|
-
|
|
Feb 04
2025
|
Jonathan Biller EVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,744
+18.15%
|
-
|
|
Feb 04
2025
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
BUY
Grant, award, or other acquisition
|
Direct |
9,876
+17.53%
|
-
|
|
Feb 04
2025
|
Kristen Ambrose SVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,420
+16.89%
|
-
|
|
Feb 04
2025
|
Stuart A Arbuckle EVP, COO |
BUY
Grant, award, or other acquisition
|
Direct |
23,072
+14.46%
|
-
|